文献速递乳腺癌放疗放疗物理与技术

早期乳腺癌每周两次5次28Gy超大分割全乳放疗的毒性与美容结局

Toxicity and Cosmetic Outcomes of 28 Gy in 5 Fractions Twice per Week Ultrahypofractionated Whole-Breast Irradiation in Early-Stage Breast Cancer.
PubMed 文献 · Pract Radiat Oncol · 2026-07-10

该回顾性单中心研究纳入94例导管原位癌或早期浸润性乳腺癌患者,术后接受28Gy分5次、每周两次的超大分割全乳放疗,采用3D-CRT技术并以俯卧位为标准体位。未观察到3级及以上急慢性毒性,1年美容评估优良率达98.8%,提示该方案安全可行且美容结局可接受。

要点

  • 94例早期乳腺癌术后患者接受28Gy分5次每周两次全乳放疗,均采用3D-CRT,96.8%俯卧位。
  • 未观察到3级及以上急性或晚期毒性,最常见急性1-2级毒性为乏力(71%)和皮炎(53.3%)。
  • 1年时美容评估可获取80例,98.8%为优良、1.2%为一般。

核心结论

  • 28Gy分5次每周两次俯卧位3D-CRT全乳放疗在该回顾性队列中安全可行,美容结局可接受。

研究设计与样本

  • 回顾性单中心研究,纳入2020年2月至2025年3月94例导管原位癌或早期浸润性乳腺癌术后患者。
  • 放疗方案为28Gy分5次、每周两次,采用3D-CRT技术,俯卧位为标准体位。
  • 急性与晚期毒性按NCI CTCAE v5.0分级,美容结局由医生采用Harvard量表评估。

主要发现

  • 中位年龄72岁,T1期占69.1%,单纯导管原位癌占18.1%,雌激素受体阳性占92.6%。
  • 未观察到3级及以上急性或晚期毒性。
  • 常见急性1-2级毒性包括乏力71%、皮炎53.3%、色素沉着29.9%、乳房疼痛29.3%、乳房水肿24.4%、瘙痒17.7%。
  • 1年时常见晚期毒性为皮肤硬结75.8%、乏力58.8%、乳房萎缩56.9%、色素沉着54.1%。
  • 1年美容评估80例中,优良占98.8%,一般占1.2%。

关键数值与推荐

  • 放疗剂量方案为28Gy分5次、每周两次。
  • 3D-CRT技术,96.8%患者采用俯卧位。
  • 毒性分级采用NCI CTCAE v5.0,美容结局采用Harvard量表。

临床怎么用

  • 该方案可作为早期乳腺癌术后全乳放疗的超大分割可选方案,尤其适合俯卧位3D-CRT条件下治疗。
  • 治疗中需关注乏力、皮炎等急性1-2级毒性及1年时皮肤硬结、乳房萎缩等晚期改变。

局限性

  • 回顾性单中心设计,样本量94例,随访时间有限。
  • 作者指出需更长时间随访和更大样本研究验证 findings 及评估长期临床结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The UK FAST and FAST-Forward trials established the noninferiority of ultrahypofractionated whole-breast irradiation delivered in 5 fractions with respect to local control, toxicity, and cosmetic outcomes. The optimal regimen and technical approach for ultrahypofractionated adjuvant radiation therapy, however, remain uncertain. METHODS AND MATERIALS: This retrospective, single-institution study included women with ductal carcinoma in situ or early-stage invasive breast cancer who underwent lumpectomy followed by adjuvant whole-breast irradiation of 28 Gy in 5 fractions, delivered twice per week. Radiation was delivered using a 3-dimensional conformal radiation therapy (3D-CRT) technique, with the prone position used as the standard setup. Acute and late radiation toxicities were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, and cosmetic outcomes were evaluated by physicians using the Harvard scale. RESULTS: From February 2020 to March 2025, a total of 94 patients were included. The median age was 72 years. T1 disease was the most common (69.1%), and 18.1% had pure ductal carcinoma in situ. 92.6% of patients were estrogen receptor-positive and 74.5% were progesterone receptor-positive. HER2 was negative in 96.1% of invasive cases. Oncotype DX scores were available in 45.5% of invasive cases, with a median score of 16. Most patients (79.8%) received hormone therapy. All patients were treated with 3D-CRT, and 96.8% were treated in the prone position. No grade 3 or higher acute or late toxicities were observed. The most common acute grade 1 to 2 toxicities included fatigue (71%), dermatitis (53.3%), hyperpigmentation (29.9%), breast pain (29.3%), breast edema (24.4%), and pruritus (17.7%). At 1 year, the most frequent late toxicities were skin induration (75.8%), fatigue (58.8%), breast atrophy (56.9%), and hyperpigmentation (54.1%). Cosmetic assessment was available in 80 patients at 1 year, with 98.8% showing excellent-to-good and 1.2% fair results. CONCLUSIONS: An ultrahypofractionated regimen of 28 Gy in 5 fractions delivered twice weekly in the prone position using 3D-CRT appears to be safe and feasible, with acceptable cosmetic outcomes in this retrospective cohort. Further studies with longer follow-up and larger patient populations are warranted to validate these findings and assess long-term clinical outcomes.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Jitwatcharakomol T, Gokun Y, Young RL, et al. Toxicity and Cosmetic Outcomes of 28 Gy in 5 Fractions Twice per Week Ultrahypofractionated Whole-Breast Irradiation in Early-Stage Breast Cancer. Pract Radiat Oncol. 2026. PMID: 42431368. doi:10.1016/j.prro.2026.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。